Rockwell Medical (NASDAQ:RMTI – Get Rating) and 180 Life Sciences (NASDAQ:ATNF – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.
Valuation & Earnings
This table compares Rockwell Medical and 180 Life Sciences’ top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Rockwell Medical | $72.81 million | 0.45 | -$18.68 million | ($1.26) | -1.87 |
| 180 Life Sciences | N/A | N/A | -$38.73 million | ($7.20) | -0.17 |
Rockwell Medical has higher revenue and earnings than 180 Life Sciences. Rockwell Medical is trading at a lower price-to-earnings ratio than 180 Life Sciences, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rockwell Medical | 0 | 0 | 1 | 0 | 3.00 |
| 180 Life Sciences | 0 | 0 | 1 | 0 | 3.00 |
Rockwell Medical presently has a consensus price target of $7.00, suggesting a potential upside of 196.61%. Given Rockwell Medical’s higher possible upside, research analysts plainly believe Rockwell Medical is more favorable than 180 Life Sciences.
Risk and Volatility
Rockwell Medical has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, 180 Life Sciences has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500.
Institutional and Insider Ownership
27.6% of Rockwell Medical shares are owned by institutional investors. Comparatively, 15.3% of 180 Life Sciences shares are owned by institutional investors. 2.2% of Rockwell Medical shares are owned by insiders. Comparatively, 15.2% of 180 Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Rockwell Medical and 180 Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Rockwell Medical | -17.38% | -84.33% | -26.48% |
| 180 Life Sciences | N/A | -119.88% | -85.65% |
Summary
Rockwell Medical beats 180 Life Sciences on 8 of the 11 factors compared between the two stocks.
About Rockwell Medical
Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. Its products include Triferic, CitraPure, RenalPure and SteriLyte. The company was founded by Robert L. Chioini in January 1995 and is headquartered in Wixom, MI.
About 180 Life Sciences
180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palo Alto, CA.
Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.
